Latest News on CGON

Financial News Based On Company


Advertisement
Advertisement

Guggenheim raises CG Oncology stock price target on trial results

https://www.investing.com/news/analyst-ratings/guggenheim-raises-cg-oncology-stock-price-target-on-trial-results-93CH-5038658
Guggenheim has increased its price target for CG Oncology (NASDAQ:CGON) to $120 from $89, maintaining a Buy rating, following positive top-line results from the PIVOT-006 trial. This adjustment reflects increased risk-adjusted estimates for cretostimogene to $3.0 billion by 2035 and a higher probability of success in IR-NMIBC. Other firms like Truist Securities and JPMorgan also raised their price targets, while RBC Capital downgraded the stock to Sector Perform but still increased its price target.

CG Oncology CEO Arthur Kuan buys $2.4 million of stock two days after its bladder cancer trial results

https://mlq.ai/news/cg-oncology-ceo-arthur-kuan-buys-24-million-of-stock-two-days-after-its-bladder-cancer-trial-results/
CG Oncology CEO Arthur Kuan purchased 30,000.32 shares of the company's stock for approximately $2.37 million on November 18, two days after positive phase 3 trial results for its bladder cancer treatment. Chief Commercial Officer Isabel Kalofonos also bought shares worth about $299,000 through a family trust. Neither transaction was made under a Rule 10b5-1 plan, and the filings did not provide a reason for the purchases.

Director exercises $0.60 options, sells at $92 a share at CG Oncology (CGON).

https://www.stocktitan.net/sec-filings/CGON/form-4-cg-oncology-inc-insider-trading-activity-4580196bdf28.html
CG Oncology director Leonard E. Post exercised options for 1,000 shares at $0.60 each and subsequently sold 1,000 common shares at $92 per share. This transaction, which resulted in approximately $91K pre-tax spread, was conducted under a Rule 10b5-1 trading plan adopted on March 5, 2026. After the exercise, Post's post-exercise position in Director Stock Options was 101,077 underlying shares, and he held 1,000 direct common shares.

CG Oncology downgraded by RBC Capital Mkts with a new price target

https://www.quantisnow.com/insight/cg-oncology-downgraded-by-rbc-capital-mkts-with-a-new-6795688
RBC Capital Markets has downgraded CG Oncology (CGON) to Sector Perform from Outperform, setting a new price target of $97.00. This analyst rating change comes despite recent positive news regarding the company's PIVOT-006 Phase 3 trial and third-quarter financial results. Historically, CGON has shown varied stock performance following headlines, with a median move of 2.1% in either direction.

CG Oncology, Inc. Stock 12‑Month Price Target Raised to $99.85, Implies 34% Upside

https://www.tradingview.com/news/tradingview:4306bfbda5162:0-cg-oncology-inc-stock-12-month-price-target-raised-to-99-85-implies-34-upside/
The average 12-month price target for CG Oncology, Inc. stock has increased from $98.62 to $99.85, according to estimates from 13 analysts. This new target suggests a potential upside of approximately 34% from the Nov. 13 closing price. The consensus rating from 15 covering analysts remains a "Buy," with 14 Buys and 1 Hold.
Advertisement

CG Oncology's Bladder Cancer Therapy Cuts Recurrence Risk 68% in Phase 3, Setting Up Two FDA Filings

https://finance.biggo.com/news/5c0de3c4-6d80-4884-b946-a4b26df01b11
CG Oncology announced that its oncolytic virus therapy, cretostimogene grenadenorepvec, significantly reduced the risk of tumor recurrence by 68% in a Phase 3 trial for non-muscle invasive bladder cancer (NMIBC). This pivotal result paves the way for two separate FDA marketing applications in 2027, addressing intermediate-risk, high-grade Ta NMIBC and expanding its existing submission for BCG-unresponsive disease. The company highlighted the drug's strong safety profile and its potential to fill an unmet need for approximately 50,000 U.S. patients who currently lack an approved adjuvant option.

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

https://www.biopharmadive.com/news/cg-oncology-cretostimogene-adjuvant-bladder-cancer-results-pivot/874740/
CG Oncology's experimental drug, cretostimogene, significantly reduced the risk of bladder cancer recurrence in a Phase 3 trial, exceeding Wall Street's expectations. The therapy cut the relative risk of relapse by 68% and positions the company to seek clearance for early intervention in non-muscle invasive bladder cancer. This success has led to a 12% increase in company shares and positions cretostimogene as a potential "backbone" therapy across multiple treatment settings.

CG Oncology’s stock up as gene therapy gains second win in NMIBC

https://www.clinicaltrialsarena.com/news/cg-oncologys-stock-up-as-gene-therapy-gains-second-win-in-nmibc/
CG Oncology's stock surged by 23.7% after its oncolytic viral immunotherapy, cretostimogene grenadenorepvec, demonstrated significant recurrence reduction in a Phase III trial for intermediate-risk and high-grade non-muscle invasive bladder cancer (NMIBC). This second pivotal trial win will broaden the biologics licence application (BLA) the company plans to submit to the FDA, initially for BCG-unresponsive NMIBC, to also include these patient populations, with submission anticipated in Q2 2027. The positive results contribute to a growing bladder cancer market expected to reach $16bn by 2033.

CG Oncology Reports 68% Reduction in Bladder Cancer Recurrence Risk in Phase 3 PIVOT-006 Trial

https://finance.yahoo.com/healthcare/articles/cg-oncology-reports-68-reduction-160241014.html
CG Oncology announced that its Phase 3 PIVOT-006 clinical trial met its primary endpoint, demonstrating a 68% reduction in the risk of bladder cancer recurrence among patients receiving cretostimogene grenadenorepvec. The treatment was well tolerated with no Grade 3 or higher adverse events. The company plans to submit a Biologics License Application (BLA) in the second quarter of 2027 for intermediate-risk and high-grade Ta NMIBC, and an expanded application for BCG-unresponsive NMIBC by March 2027.

CG Oncology Reports 68% Lower Recurrence Risk in Phase 3 PIVOT-006 Trial

https://www.tradingview.com/news/tradingview:e68337efed6fe:0-cg-oncology-reports-68-lower-recurrence-risk-in-phase-3-pivot-006-trial/
CG Oncology announced positive results from its Phase 3 PIVOT-006 trial, where cretostimogene significantly reduced the recurrence risk by 68% in patients with intermediate-risk and high-grade Ta bladder cancer. The trial met its primary endpoint with a hazard ratio of 0.32, and no severe treatment-related adverse events were reported. The company plans to submit two Biologics License Applications (BLA) in 2027, addressing a patient population with no currently approved FDA adjuvant treatment options.
Advertisement

CGON: CG Oncology Inc. filed SEC Form 8-K: Regulation FD...

https://www.quantisnow.com/insight/cg-oncology-inc-filed-sec-form-8-k-regulation-fd-disclosure-6792510
CG Oncology Inc. reported positive topline results from its Phase 3 PIVOT-006 trial for cretostimogene in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, showing a 68% reduction in recurrence risk. These data are expected to support a second Biologics License Application (BLA) in Q2 2027, with an initial BLA for BCG-unresponsive disease being broadened and completed by March 2027. While positive for future prospects, the drug remains investigational, and commercial availability is still years away, posing ongoing regulatory risks.

2 Cancer-Drug Developers Seeing Unusual Options Volume

https://www.schaeffersresearch.com/content/options/2026/11/16/2-cancer-drug-developers-seeing-unusual-options-volume
Two cancer drug developers, Summit Therapeutics Inc (SMMT) and CG Oncology Inc (CGON), are experiencing unusual options activity following significant clinical and regulatory news. SMMT is down 15% after the FDA declined to approve its lung cancer drug, while CGON is up 12.5% after its bladder cancer treatment met its primary endpoint in a Phase 3 trial. Despite their contrasting stock movements, options traders are leaning bearish on both companies.

CG Oncology Stock In Focus After Earnings Report Shows Wider Losses

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-stock-in-focus-after-earnings-report-shows-wider
CG Oncology reported wider losses for Q3 2026, with a net loss of US$56.89 million and US$1.6 million in revenue, reflecting the high costs of advancing its drug cretostimogene. Over the first nine months of 2026, the net loss reached US$196.15 million. Analysts project significant revenue growth and a shift to profitability by 2029, but the increasing losses highlight execution risk and the importance of efficient operations to maintain its cash runway.

CG Oncology, Inc. Stock 12‑Month Price Target Raised to $92.15, Implies 31% Upside

https://www.tradingview.com/news/tradingview:e145965d4e357:0-cg-oncology-inc-stock-12-month-price-target-raised-to-92-15-implies-31-upside/
The average 12-month price target for CG Oncology, Inc. (CGON) stock has been raised from $91.46 to $92.15 by 13 analysts, with individual forecasts ranging from $80 to $112 per share. This updated target suggests a potential upside of approximately 31% based on the Nov. 12 closing price. The consensus rating from 15 analysts remains a "Buy," with 14 Buys, 1 Hold, and 0 Sells.

CG Oncology, Inc. (CGON) stock price, news, quote and history

https://au.finance.yahoo.com/quote/CGON/
This article provides a detailed overview of CG Oncology, Inc. (CGON) stock, including its current price, market performance, and key financial data. It highlights the company's focus on developing cretostimogene grenadenorepvec for bladder cancer, detailing its various clinical trial phases. The report also includes analyst insights, earnings trends, and valuation measures for investors.
Advertisement

What CG Oncology (CGON)'s Third Quarter Earnings Means For Shareholders

https://sg.finance.yahoo.com/news/cg-oncology-cgon-third-quarter-130913745.html
CG Oncology (CGON) reported third-quarter 2026 revenue of US$1.6 million and a net loss of US$56.89 million, bringing the year-to-date loss to US$196.15 million. The company's investment narrative centers on the success of its late-stage bladder cancer drug, cretostimogene, with significant spending supporting trials and commercial build-out. Analysts project substantial revenue and earnings growth by 2029, contingent on timely trial progress and regulatory approvals, while also highlighting risks related to cash burn and execution.

CG Oncology (CGON) Following Q3 Earnings Has A Stronger Case For Its Valuation

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-following-q3-earnings-has-a-stronger-case-f
CG Oncology (CGON) is back in focus after its Q3 earnings reported revenue of US$1.6 million and a narrower loss than anticipated, alongside positive updates on its late-stage bladder cancer programs. Despite recent volatility, the company's valuation is considered undervalued at $75.99 against a fair value of $91.08, supported by its cash position and potential reach of cretostimogene. Investors are advised to review the risks and rewards associated with the stock.

CG Oncology, Inc. (CGON) Misses Q3 EPS by 4c

https://www.streetinsider.com/Earnings/CG+Oncology%2C+Inc.+%28CGON%29+Misses+Q3+EPS+by+4c/27308088.html
CG Oncology, Inc. (NASDAQ: CGON) reported a Q3 EPS of ($0.64), missing analyst estimates by $0.04. The company also announced revenue for the quarter came in at $1.6 million. The stock price was up 17.27% today, trading at $75.99.

With $984.5M in cash and securities, CG Oncology (CGON) posts a wider Q3 loss.

https://www.stocktitan.net/sec-filings/CGON/10-q-cg-oncology-inc-quarterly-earnings-report-2f98200c2df2.html
CG Oncology (CGON) reported a wider net loss of $56.9 million in Q3 2026, compared to $43.8 million in Q3 2025, and a nine-month net loss of $196.1 million. Despite the losses, the late-stage clinical biopharmaceutical company holds $984.5 million in cash, cash equivalents, and marketable securities, which management believes will fund operations for at least the next twelve months. The company is advancing its lead product candidate, cretostimogene, for bladder cancer, with a Biologics License Application submission expected in Q4 2026.

CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates

https://finance.yahoo.com/markets/stocks/articles/cg-oncology-inc-cgon-reports-135501399.html
CG Oncology, Inc. (CGON) reported a Q3 loss of $0.64 per share, surpassing the Zacks Consensus Estimate of a $0.86 loss and an earnings surprise of +25.58%. The company also exceeded revenue estimates, posting $1.6 million against a consensus of $1.08 million. CGON shares have seen a significant gain of 56.1% year-to-date, outperforming the S&P 500.
Advertisement

CG Oncology, Inc. (CGON) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/CGON/
CG Oncology, Inc. (CGON) closed at $67.71, up 5.70%, on November 4th, with significant year-to-date and one-year returns of 63.08% and 73.30% respectively. The biopharmaceutical company is actively developing cretostimogene grenadenorepvec, an oncolytic immunotherapy, for bladder cancer with multiple product candidates in Phase 2 and Phase 3 clinical trials. Analysts currently have an average price target of $91.08 with a "Neutral" Zacks Rating and a majority of "Strong Buy" or "Buy" recommendations.

Genmab Share Price Surge Puts These Oncology Stocks In Focus

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/genmab-share-price-surge-puts-these-oncology-stocks-in-focus/amp
Following Genmab's significant share price surge and three Phase 3 wins, attention is turning to other oncology biotech companies. This article examines three specific oncology stocks—CG Oncology, BeOne Medicines, and Zymeworks—that are directly influenced by Genmab's success. It explores their current development stages, market positions, and the unique factors that could impact their future earnings, providing insight for investors seeking opportunities or assessing risks in the sector.

CG Oncology, Inc. (CGON) Seasonal returns chart

https://uk.finance.yahoo.com/quote/CGON/seasonality/
The article provides a seasonal returns chart for CG Oncology, Inc. (CGON), displaying the average monthly price return from 2024 to 2026. It includes current stock information, showing CGON trading at 64.68 USD with a slight increase. The page also offers various financial data points like news, statistics, and historical data for the company.

CG Oncology, Inc. Estimates – NASDAQ:CGON

https://www.tradingview.com/symbols/NASDAQ-CGON/financials-estimates/
This article from TradingView provides an overview of CG Oncology, Inc. (NASDAQ:CGON) financial estimates. It allows users to explore reported financial data and analyst estimates, comparing actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.

CG Oncology, Inc. Estimates – BOATS:CGON

https://www.tradingview.com/symbols/BOATS-CGON/financials-estimates/
This article provides an overview of CG Oncology, Inc. (CGON) financial estimates available on TradingView. It highlights sections for exploring reported financial data, analyst estimates across various statements, and comparing actual results with projections. The platform allows users to visualize trends over time for income statements, balance sheets, and cash flow data on both annual and quarterly bases.
Advertisement

How Investors May Respond To CG Oncology (CGON) Hiring A Commercial Chief

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/how-investors-may-respond-to-cg-oncology-cgon-hiring-a-comme
CG Oncology recently appointed Isabel Kalofonos as Chief Commercial Officer, bringing over 20 years of biopharma commercial leadership as the company prepares for the potential commercialization of cretostimogene grenadenorepvec in bladder cancer. This move is expected to address execution risk for its first product launch and support the company's plan for a lean in-house commercial build. Analysts project significant revenue growth and a shift to profitability by 2029, with Kalofonos's role being crucial in managing selling costs and driving product uptake.

CG Oncology's CCO Isabel Kalofonos Awarded 92,000 Stock Options on October 15, 2026

https://kalkinemedia.com/us/news/announcements/cg-oncologys-cco-isabel-kalofonos-awarded-92000-stock-options-on-october-15-2026
Isabel Kalofonos, Chief Commercial Officer of CG Oncology, Inc. (NASDAQ:CGON), was granted 92,000 employee stock options on October 15, 2026. These options have an exercise price of $61.86, expire on October 14, 2036, and will vest over four years, with 25% vesting after 12 months and the remainder in monthly installments, contingent on her continuous service. This grant was disclosed in a Form 4 filed on October 19, 2026.

A director sells 1,000 CG Oncology (CGON) shares and exercises options at $0.60.

https://www.stocktitan.net/sec-filings/CGON/form-4-cg-oncology-inc-insider-trading-activity-af5fe4f7bba8.html
CG Oncology director Leonard E. Post exercised options for 1,000 common shares at $0.60 each and subsequently sold these shares in two blocks on October 15, 2026. The sales, totaling 1,000 shares, were executed under a Rule 10b5-1 trading plan for weighted average prices of $61.65 and $62.48 per share. Following these transactions, Post's reported post-exercise director stock option position was 102,077 shares.

[Form 3] CG Oncology, Inc. Initial Statement of Beneficial Ownership

https://www.stocktitan.net/sec-filings/CGON/form-3-cg-oncology-inc-initial-statement-of-beneficial-ownership-79881c2db8ab.html
Isabel Kalofonos, the new Chief Commercial Officer of CG Oncology, Inc. (CGON), filed an Initial Statement of Beneficial Ownership of Securities (Form 3) on October 19, 2026. The filing indicates that Kalofonos does not beneficially own any securities of the company as of the event date, October 13, 2026. This Form 3 is a standard SEC filing for new officers to declare their initial holdings.

Form 144 CG Oncology For: 15 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-cg-oncology-for-15-october-93CH-2739560
This article from Investing.com reports the filing of Form 144 for CG Oncology on October 15th. The content is brief, primarily serving as a notification of the filing and listing CG Oncology's stock symbol CGON, which shows a slight decline.
Advertisement

A director plans to sell 3,000 shares of CG Oncology (NASDAQ: CGON).

https://www.stocktitan.net/sec-filings/CGON/144-cg-oncology-inc-sec-filing-26af70b70f09.html
CG Oncology director Leonard Post plans to sell 3,000 common shares with an aggregate market value of $185,520, according to a Form 144 SEC filing. These shares are expected to be received through stock-option exercises over the next three months. The filing also reports two prior Rule 10b5-1 sales by Post in August and September 2026.

CG Oncology (CGON) Names New Commercial Chief As Valuation Turns Back To Cretostimogene

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/cg-oncology-cgon-names-new-commercial-chief-as-valuation-tur
CG Oncology (CGON) has appointed Isabel Kalofonos as Chief Commercial Officer, preparing for the potential launch of cretostimogene grenadenorepvec. Despite recent stock price drops, year-to-date returns are up significantly, indicating a mixed investor sentiment balancing launch risks against leadership appointments. The company is considered undervalued by analysts, with a fair value around $91.08 per share, but faces risks from regulatory pricing and operating costs.

CG Oncology appoints Isabel Kalofonos as chief commercial officer

https://www.investing.com/news/company-news/cg-oncology-appoints-isabel-kalofonos-as-chief-commercial-officer-93CH-4946534
CG Oncology, Inc. (NASDAQ:CGON) has appointed Isabel Kalofonos as its new Chief Commercial Officer. Kalofonos brings over 20 years of biopharmaceutical commercial leadership experience, having previously served at Crinetics Pharmaceuticals and ImmunoGen. She will lead CG Oncology's commercial strategy, focusing on the potential launch of cretostimogene grenadenorepvec, an investigational bladder cancer treatment with FDA Fast Track and Breakthrough Therapy designations.

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

https://www.manilatimes.net/2026/10/13/tmt-newswire/globenewswire/cg-oncology-appoints-proven-biopharmaceutical-commercial-leader-isabel-kalofonos-as-chief-commercial-officer/2444588
CG Oncology has appointed Isabel Kalofonos as its Chief Commercial Officer, leveraging her over 20 years of biopharmaceutical commercial leadership experience. Ms. Kalofonos will be responsible for leading the company's commercial strategy and execution, particularly as it prepares for the potential launch of its bladder cancer therapeutic, cretostimogene grenadenorepvec. Her extensive background includes successful product launches and building commercial organizations across various therapeutic areas.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

https://www.morningstar.com/news/pr-newswire/20261012ny70331/kuehn-law-encourages-investors-of-cg-oncology-inc-to-contact-law-firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential breaches of fiduciary duties by certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON). The investigation focuses on potential self-dealing, and the firm encourages long-term CGON stockholders to contact them for a free consultation regarding potential damages and corporate governance reforms. Shareholders are urged to act promptly as there may be limited time to enforce their rights.
Advertisement

Investigation launched into CG Oncology officers for possible self-dealing harming shareholders

https://pluang.com/en/news-feed/kuehn-law-ajak-pemegang-saham-cg-oncology-hubungi-kantor-hukum
Kuehn Law, PLLC has initiated an investigation into CG Oncology, Inc. officers and directors for potential self-dealing and breaches of fiduciary duties. This probe aims to protect shareholder rights and may lead to corporate governance reforms and damages for investors. Long-term shareholders are encouraged to contact the law firm promptly.

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-cg-oncology-inc-to-contact-law-firm-302906221.html
Kuehn Law, PLLC is investigating whether officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders due to potential self-dealing. The firm encourages long-term CGON stockholders to contact them for a free consultation regarding potential damages and corporate governance reforms. Shareholders are urged to act promptly as there may be limited time to enforce their rights.

Form DEF 14A CG Oncology Inc For: 11 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-def-14a-cg-oncology-inc-for-11-october-93CH-2730457
This article announces the filing of Form DEF 14A by CG Oncology Inc. on October 11, 2026. The brief entry provides the company name and filing date, indicating a regulatory disclosure event. No further details about the content of the filing are provided within the article itself.

Moderna Stock Surge Puts These Oncology Biotechs On Retail Investors Radar

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/moderna-stock-surge-puts-these-oncology-biotechs-on-retail-i/amp
Following a 14% surge in Moderna's stock due to a renewed focus on oncology, this article highlights three biotechnology companies that retail investors should watch. CG Oncology, TriSalus Life Sciences, and Legend Biotech are presented as potential beneficiaries of increased interest in next-generation cancer therapies, particularly those utilizing AI and mRNA tools. The article provides a brief overview of each company's oncology focus, market cap, and key developments.

Moderna Stock Surge Puts These Oncology Biotechs On Retail Investors Radar

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgon/cg-oncology/news/moderna-stock-surge-puts-these-oncology-biotechs-on-retail-i
Moderna's recent 14% stock jump, driven by advancements in oncology through AI and mRNA tools, has highlighted several biotech companies focusing on next-generation cancer therapies. This article reviews three such companies: CG Oncology, TriSalus Life Sciences, and Legend Biotech, providing insights into their market position, therapeutic approaches, and potential for growth in the evolving cancer research landscape.
Advertisement

CG Oncology (CGON) Short Interest & Short Float | Updated Sep 2026

https://www.marketbeat.com/stocks/NASDAQ/CGON/short-interest/
CG Oncology (CGON) had a short interest of 11.25 million shares as of September 15, 2026, representing 13.34% of its public float, which is a 1.24% decrease from the previous report. The short interest ratio is 17.0 days to cover, indicating strong pessimism about the stock. This report provides historical short interest data, frequently asked questions, and comparisons to competitors in the biotechnology industry.

After $7.9M sale, CG Oncology (NASDAQ: CGON) officer plans more stock trades

https://www.stocktitan.net/sec-filings/CGON/144-cg-oncology-inc-sec-filing-ebbe672c3678.html
CG Oncology (NASDAQ: CGON) officer Ambaw Bellete has filed a Rule 144 notice indicating an intended sale of 30,787 shares of common stock, tied to a stock option exercise, with Morgan Stanley Smith Barney LLC handling the transaction on NASDAQ. The filing also reveals numerous prior sales by Bellete over the past three months, including a significant sale of 100,000 shares on August 19, 2026, valued at over $7.9 million. These transactions highlight insider activity and potential market impact for CGON investors.

CG Oncology (NASDAQ: CGON) officer sold 100,000 shares and now plans more

https://www.stocktitan.net/sec-filings/CGON/144-cg-oncology-inc-sec-filing-4ef4fa521d53.html
An officer at CG Oncology (CGON), Ambaw Bellete, has filed a Rule 144 notice to sell 6,532 shares of common stock, valued at approximately $499,698, after previously selling 100,000 shares for over $7.9 million on August 19, 2026. The filing indicates a stock option exercise and multiple other significant sales by Bellete in the past three months, alongside the company's reported 88,640,375 shares outstanding. This proposed sale will be executed through Morgan Stanley Smith Barney.

CG Oncology (NASDAQ: CGON) director sells shares under preset trading plan

https://www.stocktitan.net/sec-filings/CGON/form-4-cg-oncology-inc-insider-trading-activity-fb3aaaef2363.html
CG Oncology director Leonard E. Post exercised options for 1,000 shares and simultaneously sold them at a weighted average price of $72.98 under a pre-arranged Rule 10b5-1 trading plan. The transaction resulted in an approximate pre-tax spread of $72,000. Following these transactions, Post directly held 103,077 option-based rights.

CG Oncology at Cantor conference: cretostimogene nears key readout

https://in.investing.com/news/stock-market-news/cg-oncology-at-cantor-conference-cretostimogene-nears-key-readout-93CH-5587489
CG Oncology discussed its lead drug, cretostimogene, for non-muscle invasive bladder cancer (NMIBC) at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company is nearing a key Phase III readout for intermediate-risk NMIBC, advancing manufacturing for its initial BLA, and planning a third Phase III trial for BCG-exposed high-risk disease. Despite strong clinical progress, the company acknowledges market competition and the need to demonstrate real-world adoption, with financial profitability not expected until after 2026.
Advertisement

Planned CG Oncology (NASDAQ: CGON) insider sale totals 826 shares

https://www.stocktitan.net/sec-filings/CGON/144-cg-oncology-inc-sec-filing-07f0ba2d9b92.html
An officer at CG Oncology (NASDAQ: CGON), Ambaw Bellete, plans to sell 826 shares of common stock for $61,950 on September 11, 2026, following a stock option exercise. This information comes from a Rule 144 SEC filing. The filing also details numerous prior sales by Bellete over the preceding three months, including a 100,000-share sale for over $7.9 million on August 19, 2026.

Bank of New York Mellon Corp Invests $16.58 Million in CG Oncology, Inc. $CGON

https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-invests-1658-million-in-cg-oncology-inc-cgon-2026-09-01/
Bank of New York Mellon Corp has acquired a new stake of 233,419 shares in CG Oncology, Inc. (NASDAQ:CGON), valued at approximately $16.58 million, representing 0.26% of the company. Institutional investors collectively own 26.56% of CG Oncology. Despite insider activity showing both buying and selling, and the company missing its quarterly EPS estimate, analysts maintain a consensus "Moderate Buy" rating with an average price target of $83.18.

CG Oncology, Inc. $CGON Shares Sold by Wellington Management Group LLP

https://www.marketbeat.com/instant-alerts/filing-cg-oncology-inc-cgon-shares-sold-by-wellington-management-group-llp-2026-08-31/
Wellington Management Group LLP reduced its stake in CG Oncology (NASDAQ:CGON) by 0.9% in Q2 2026, selling 46,481 shares but still holding 5.32 million shares worth $378.3 million. Analyst sentiment for CGON is largely positive, with a "Moderate Buy" consensus and an average price target of $83.18. The company reported a Q2 loss of $0.90 per share, missing estimates, but revenue exceeded expectations.

Man Group plc Takes $3.68 Million Position in CG Oncology, Inc. $CGON

https://www.marketbeat.com/instant-alerts/filing-man-group-plc-takes-368-million-position-in-cg-oncology-inc-cgon-2026-08-31/
Man Group plc has acquired a significant position in CG Oncology, Inc. (NASDAQ:CGON), purchasing 51,849 shares valued at approximately $3.68 million in the second quarter. This investment makes Man Group plc an approximate 0.06% owner of the company, highlighting institutional interest in the biopharmaceutical firm. Despite the company reporting a quarterly loss that missed analyst estimates, its revenue exceeded expectations, and analysts maintain a "Moderate Buy" consensus with an $83.18 price target.

California loses another multibillion-dollar company to Texas

https://www.sfgate.com/california/article/biotech-company-relocates-texas-22406522.php
Biotech company CG Oncology, valued at $7 billion, has moved its headquarters from Irvine, California, to Dallas, Texas, signing an eight-year lease at Pegasus Park. The company, which focuses on bladder cancer immunotherapy, cited better access to talent and new facilities as reasons for the relocation. This move follows a trend of other California-headquartered companies relocating to Texas.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement